Immatics NV
NASDAQ:IMTX
Immatics NV
Revenue
Immatics NV
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Immatics NV
NASDAQ:IMTX
|
Revenue
€54m
|
CAGR 3-Years
20%
|
CAGR 5-Years
70%
|
CAGR 10-Years
N/A
|
|
BioNTech SE
NASDAQ:BNTX
|
Revenue
€3.8B
|
CAGR 3-Years
99%
|
CAGR 5-Years
97%
|
CAGR 10-Years
N/A
|
|
MorphoSys AG
XETRA:MOR
|
Revenue
€238.3m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
26%
|
CAGR 10-Years
12%
|
|
CureVac NV
NASDAQ:CVAC
|
Revenue
€53.8m
|
CAGR 3-Years
3%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
Biotest AG
XETRA:BIO
|
Revenue
€684.6m
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
3%
|
|
Formycon AG
XETRA:FYB
|
Revenue
€42.5m
|
CAGR 3-Years
8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
See Also
What is Immatics NV's Revenue?
Revenue
54m
EUR
Based on the financial report for Dec 31, 2023, Immatics NV's Revenue amounts to 54m EUR.
What is Immatics NV's Revenue growth rate?
Revenue CAGR 5Y
70%
Over the last year, the Revenue growth was -69%. The average annual Revenue growth rates for Immatics NV have been 20% over the past three years , 70% over the past five years .